Business
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
– On track to achieve FY 2025 financial guidance; raised adjusted EBITDA guidance to greater than $105 million for 2025 – – LINZESS® (linaclotide) EUTRx
About this update from Ironwood Pharmaceuticals, Inc.
[{"type":"text","content":"\n– On track to achieve FY 2025 financial guidance; raised adjusted EBITDA guidance to greater than $105 million for 2025 –\n\n– LINZESS® (linaclotide) EUTRx prescription demand growth of 8% year-over-year; in line with full-year expectations –\n\n– Exploring strategic alternatives to maximize stockholder value –\n\n BOSTON--(BUSINESS WIRE)--\nIronwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance.\n\n“LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and further, recently raised our adjusted EBITDA guidance. We are making a concerted effort to maximize stockholder value across all areas of the business, including advancing plans for a confirmatory Phase 3 trial for apraglutide and exploring strategic alternatives,” said Tom McCourt, chief executive officer of Ironwood.\n\nFirst Quarter 2025 Financial Highlights1\n(in thousands, except for per share amounts)\n\n\n\n \n\n\n\n \n\n\n\nQ1 2025\n\n\n\n\nQ1 2024\n\n\n\n\n\nTotal revenue 2\n\n\n\n\n$41,143\n\n\n\n\n$74,877\n\n\n\n\n\nTotal costs and expenses\n\n\n\n\n70,251\n\n\n\n\n63,857\n\n\n\n\n\nGAAP net loss\n\n\n\n\n(37,386)\n\n\n\n\n(4,162)\n\n\n\n\n\nGAAP net loss – per share basic and diluted\n\n\n\n\n(0.23)\n\n\n\n\n(0.03)\n\n\n\n\n\nAdjusted EBITDA3\n\n\n\n\n(4,742)\n\n\n\n\n21,142\n\n\n\n\n\nNon-GAAP net loss\n\n\n\n\n(23,228)\n\n\n\n\n(2,933)\n\n\n\n\n\nNon-GAAP net loss per share – basic and diluted\n\n\n\n\n(0.14)\n\n\n\n\n(0.02)\n\n\n\n\n\n\n1 Refer to the Reconciliation of GAAP Results to Non-GAAP Financial Measures table and to the Reconciliation of GAAP Net Loss to Adjusted EBITDA table at the end of this press release. Refer to Non-GAAP Financial Measures for additional information.\n\n\n\n\n\n\n\n\n2 Total revenue for three months ended March 31, 2025 reflects a change in estimate of AbbVie gross-to-net rebate reserves, which was refined to reflect rebates owed for units dispensed in the first quarter of 2025. Ironwood does not expect first quarter LINZESS U.S. net sales results or this change in estimate to impact the full-year results.\n\n\n\n\n\n\n\n\n3 Adjusted EBITDA is calculated by subtracting restru...